We continue to expand on our history of bringing scientific breakthroughs to people living with chronic diseases like obesity and diabetes. Our new collaboration and license agreement with Septerna Inc. that we have just announced will help us on that mission. Learn more below or in our press release here https://lnkd.in/gu4MH2U
Novo Nordisk
Fabricación de productos farmacéuticos
Get updates around our progress and challenges to champion long-term health 💙 #DrivingChange
Sobre nosotros
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. For more information visit novonordisk.com. This page isn’t intended for discussions about products. As such, postings or comments that contain product discussions may be removed. This page is for discussions about Novo Nordisk and its subsidiaries and the initiatives and projects we are involved in. While we welcome everyone to make comments, we reserve the right to remove those that are off-topic, abusive or intended to spam. Any questions specific to products should be made to your healthcare professional. If you wish to file an adverse drug reaction please Novo Nordisk’s office in the country you live in: https://www.novonordisk.com/-us/find-local-information.html For other customer complaints, please us here: https://www.novonordisk.com/-us.html Please keep in mind that Novo Nordisk A/S and its subsidiaries work within a highly regulated industry. Therefore, comments that pertain to legal matters or regulatory issues may be removed. Comments contained on this site come from of the public, and do not necessarily reflect the views of Novo Nordisk A/S. Novo Nordisk A/S does not endorse or approve any content added by other LinkedIn s. Learn more about our privacy disclaimer and community guidelines here: https://www.novonordisk.com/data-privacy-and--rights/social-media-privacy-disclaimer.html
- Sitio web
-
https://www.novonordisk.com
Enlace externo para Novo Nordisk
- Sector
- Fabricación de productos farmacéuticos
- Tamaño de la empresa
- Más de 10.001 empleados
- Sede
- Bagsværd
- Tipo
- Empresa pública
- Fundación
- 1923
- Especialidades
- Pharmaceuticals, Insulin, obesity, Rare Diseases y Diabetes
Ubicaciones
Empleados en Novo Nordisk
-
Karen J. Kolin
Clinical Research Relationship Specialist
-
Thomas Røygaard
PMO | Digital Transformation | Leading Program, Project and Portfolio Management | Governance | Change Management
-
Sören Meelby
Digital Healthcare Evangelist | Cultivating Partnerships for Collective Impact & Social Good
-
Henrik Vestergaard
Actualizaciones
-
Our results from the first three months of 2025 are out. Thanks to all colleagues and partners across the world for continuing to drive change towards long-term health. Read more here 👉 https://lnkd.in/gu4MH2U #NovoNordisk #QuarterlyResults
-
Did you know that obesity is linked to over 200 complications? Obesity isn’t just about a number on a scale. It's about long-term health, which is why knowing how it affects other health problems matters for both prevention and treatment. Vote below or add your thoughts in the comments 👇 #DrivingChange #Obesity
El contenido no está disponible aquí
Accede a este contenido y mucho más en la aplicación de LinkedIn
-
Haemophilia is a rare bleeding disorder that prevents blood from clotting properly. Advances in care have changed lives, yet 81% of people living with haemophilia still experience bleeds. Even with progress, there’s more to be done. Vote below or add your thoughts in the comments 👇 #WorldHaemophiliaDay #WHD2025
El contenido no está disponible aquí
Accede a este contenido y mucho más en la aplicación de LinkedIn
-
Obesity isn’t just about a number on a scale. It’s about long-term health. Did you know that obesity is linked to over 200 complications including type 2 diabetes, cardiovascular disease, and liver disease? Learn more about our mission to defeat obesity here: https://lnkd.in/eCyWpsQ #NovoNordisk #DrivingChange #Obesity
-
How do we encourage long-term health at work? Almost 9,000 colleagues from all over the world took part in our company-wide Stay Active Month – an initiative that not only encourages movement but also builds a stronger sense of community among colleagues. From running to winter bathing and cycling, together, we aim to inspire each other to integrate more physical activity into our daily lives! Tell us in the comments what you do to create an active community at your workplace 👇 #DrivingChange
-
-
-
-
-
+2
-
-
We have entered a license agreement with United Biotechnologies for an investigational medicine for obesity and type 2 diabetes called UBT251. Get the facts below or learn more in our press release here https://lnkd.in/gu4MH2U #DrivingChange #Innovation
-
Obesity isn’t straightforward. In 50 years, obesity rates have tripled – and they’re still going up. Has there really been a global loss of willpower or is there something more complex going on? To tackle all the complex issues out there, it'll take some out-there answers. Now is the time to do things differently. #NovoNordisk #DrivingChange #Obesity
-
Women are driving change every day—across research, production, and beyond. This #InternationalWomensDay, we’re celebrating those who #AccelerateAction for a healthier future. From the science behind producing life-saving medicines to fostering mentorship, these women and their allies are shaping long-term health solutions for generations to come. Who inspires you to take action? Tag them below 👇 #DrivingChange #IWD2025
Páginas similares
Acciones
NVO
NYSE
20 minutos de retraso
68,17 US$
-0,03 (-0,044 %)
- Apertura
- 66,41
- Mínimo
- 66,36
- Máximo
- 68,515
Datos de Refinitiv
Consulta más información enFinanciación
Novo Nordisk
1 ronda en total
Ver más información en Crunchbase
Última ronda
Equidad tras OPV
Enlace externo a Crunchbase para la última ronda de financiación
22.000.000,00 US$